Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05932927 |
| Other study ID # |
2022-096 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 1, 2023 |
| Est. completion date |
June 1, 2024 |
Study information
| Verified date |
July 2023 |
| Source |
Beijing YouAn Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Hepatopulmonary syndrome (HPS) has unknown pathogenesis, limited treatment and poor
prognosis. The onset of HPS is insidious and easy to be ignored. Many liver diseases such as
"cirrhosis and related complications" are the core characteristics of Beijing You 'an
Hospital, but the clinical characteristics of HPS patients in the center are still unclear.
The investigators plan to make the diagnosis of HPS among chronic liver disease patients in
the hospital according to the diagnostic criteria of HPS proposed in the Practice Guidelines
of the International Society of Liver Transplantation in 2016, collect clinical data of HPS
participants, evaluate the severity, analyze and summarize clinical characteristics, and
conduct management and follow-up. At the same time, The investigators collect blood samples
for proteomics tests. In order to improve the diagnosis and treatment level of HPS.
Description:
At present, the mechanism of hepatopulmonary syndrome is not clear. The researchers plan to
use the extracted plasma for detection, protein extraction and quality control, and then
proteolytic hydrolysis, computer detection, and bioinformatics analysis.
